跳至主要内容
临床试验/NCT06535555
NCT06535555撤回不适用

Safety and Feasibility of ActivSight(tm) in the Identification of The Ureter Via Riboflavin Fluorescence

Activ Surgical2 个研究点 分布在 1 个国家开始时间: 2023年3月最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
试验地点
2
主要终点
Ease of use

研究概览

简要总结

The main Objective of this study is to determine the safety and feasibility of a prototype ActivSightTM in identifying the ureter in real-time during elective laparoscopic abdominopelvic surgery after pre-surgical administration of riboflavin. This study seeks to identify the ureter only; ActivSight™ will not be used to Safety and Feasibility of ActivSightTM in the Identification of the Ureter via Riboflavin Fluorescence guide treatment or the surgical procedure. As such, this is a non-significant risk study. Riboflavin is a common dietary supplement and will be administered at dosages shown previously to be well-tolerated for migraine prophylaxis [6]. ActivSight™ is an imaging system connected to the standard laparoscopic system already existing in the OR at the site. Changes made to the commercial ActivSight™ hardware for this study introduce no significant risk

详细描述

In the 2019 publication, "A zwitterionic near-infrared fluorophore for real-time ureter identification during laparoscopic abdominopelvic surgery," by de Valk, et al. [1], the authors present the clinical need for real-time identification of the ureter during laparoscopic abdominal surgery: "Iatrogenic ureteral injury is amongst the most feared complications of lower abdominal surgery, with incidence varying from 0.5 - 1% in cancer surgery, to as high as 10% in gynecologic oncologic surgery [2-5]. Ureters are thin-walled and at risk for injury as they are poorly distinguished from surrounding retroperitoneal tissue and are usually in a collapsed state. Unrecognized ureteral damage during surgery can lead to long-term morbidity, including kidney failure." In their publication, this team proposes the use of a zwitterionic near-infrared fluorophore that could be detected in real-time via near-infrared fluorescence imaging. Activ Surgical has developed and commercialized ActivSight™, a near-infrared fluorescence detector, that combines an innovative form factor and proprietary software to deliver precise, objective, cost efficient real-time visualization of blood flow and tissue perfusion intraoperatively for laparoscope-based surgery. A small adaptor fits between any existing laparoscope and camera system and a separate light source is placed along any current commercial system to deliver objective real-time tissue perfusion and blood flow information intraoperatively. ActivSight™ received 510(k) clearance from the US FDA in 2020. According to its labelling, ActivSight™ is intended to provide real-time endoscopic fluorescence and near infrared imaging. ActivSight™ enables surgeons to visually assess blood flow and related tissue perfusion using fluorescence and near infrared imaging, and at least one of the major bile ducts (cystic duct, common bile duct or common hepatic duct) using fluorescence, all during minimally invasive surgery. In this clinical feasibility study, Activ Surgical proposes a slightly different approach from the above-referenced publication to achieve real-time ureter identification during elective laparoscopic abdominal surgery. Instead of utilizing a zwitterionic fluorophore to fluoresce the ureter, Activ Surgical is investigating a common over-the-counter water-soluble vitamin: riboflavin, also known as vitamin B2.

While typically administered as a dietary supplement, the medical literature contains many large studies of riboflavin use as prophylaxis for migraines [6]. It has also been studied and used to identify ureteral jets during cystoscopy as a method of confirming ureter patency after pelvic prolapse surgery [7-8].

Riboflavin possesses properties of fluorescence, with three strong areas of fluorescence [9] in the visible wavelength spectrum. To detect the fluorescence of riboflavin, changes were made to ActivSight™ hardware for this study; these changes are detailed herein. The main Objective of this study is to determine the safety and feasibility of a prototype ActivSightTM in identifying the ureter in real-time during elective laparoscopic abdominopelvic surgery after pre-surgical administration of riboflavin. This study seeks to identify the ureter only; ActivSight™ will not be used to guide treatment or the surgical procedure. As such, this is a non-significant risk study. Riboflavin is a common dietary supplement and will be administered at dosages shown previously to be well-tolerated for migraine prophylaxis [6]. ActivSight™ is an imaging system connected to the standard laparoscopic system already existing in the OR at the site. Changes made to the commercial ActivSight™ hardware for this study introduce no significant risk. Subjects presenting for elective laparoscopic abdominopelvic surgery (meeting the inclusion/exclusion criteria detailed below) will be consented and asked to permit the surgeons to identify their ureter with the prototype ActivSight™ system during elective laparoscopic surgery after ingesting the proper dosage of riboflavin pre-surgery. Video of the ureter examination will be recorded and analyzed post-surgery; retained video will be devoid of any protected health information.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Device Feasibility
盲法
None

入排标准

年龄范围
21 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Ages 22 to 65 presenting for elective laparoscopic abdominopelvic surgery
  • No contraindication to riboflavin and able to ingest riboflavin in pill form
  • Willing and able to consent to the study
  • Native language is English or proficient in both written and spoken English

排除标准

  • Known or suspected history of any of the following:
  • Kidney or liver disease
  • Vitamin deficiency or transporter deficiency or metabolic disorder
  • Pelvic surgery (including gynecologic, colorectal, urologic, etc.)
  • Pelvic radiation
  • Abdominopelvic trauma
  • Ureteral injury or presence of ureteral stent(s)
  • Bladder injury
  • Kidney stones
  • Inflammatory bowel disease
  • Neurologic disorder, including seizure or stroke history (history of migraine is acceptable)
  • Any form of diabetes
  • Active malignancy
  • Uncontrolled hypertension
  • Multiple chronic recurring urinary tract infections (isolated urinary tract infections are acceptable)
  • BMI > 35 kg/m2
  • Pregnant or lactating

结局指标

主要结局

Ease of use

时间窗: Immediately post-operative

1-5 point scale, surgeon assessment of how easy the technology was to use intraoperatively

Time required to identify ureter

时间窗: Immediately post-operative

1-5 point scale, surgeon assessment of how much time it took to identify the ureter

Ureteral visibility

时间窗: Immediately post-operative

1-5 point scale, surgeon assessment of how visible the ureter was on imaging

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Safety and Feasibility of ActivSight(tm) in the... | 临床试验